MASLD, MLA Pesarattu and Other Developments.
作者信息
Anand Anil C
机构信息
Department of Gastroenterology & Hepatology, Kalinga Institute of Medical Sciences, Bhubneshwar, India.
出版信息
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102465. doi: 10.1016/j.jceh.2024.102465. Epub 2024 Nov 22.
Abstract
摘要
相似文献
1
MASLD, MLA Pesarattu and Other Developments.代谢功能障碍相关脂肪性肝病、MLA佩萨拉图及其他进展
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102465. doi: 10.1016/j.jceh.2024.102465. Epub 2024 Nov 22.
2
Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).瑞美替隆：代谢功能障碍相关脂肪性肝病（MASLD）治疗的一项突破。
Health Sci Rep. 2025 Jun 18;8(6):e70920. doi: 10.1002/hsr2.70920. eCollection 2025 Jun.
3
The Rising Global Burden of MASLD and Other Metabolic Diseases (2000-2021).2000年至2021年全球非酒精性脂肪性肝病及其他代谢性疾病负担的上升
United European Gastroenterol J. 2025 Sep;13(7):1141-1154. doi: 10.1002/ueg2.70072. Epub 2025 Jul 3.
4
The serum uric acid to apolipoprotein A1 ratio is independently correlated with metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: findings from a single national metabolic management center cohort.血清尿酸与载脂蛋白A1比值与2型糖尿病中代谢功能障碍相关脂肪性肝病独立相关：来自单一国家代谢管理中心队列的研究结果
Front Endocrinol (Lausanne). 2025 Jun 4;16:1619003. doi: 10.3389/fendo.2025.1619003. eCollection 2025.
5
Comparable Long-Term Liver Transplant Outcomes in Primary Sclerosing Cholangitis with and without MASLD: Last Decade Analysis of the UNOS Database.合并与未合并代谢相关脂肪性肝病的原发性硬化性胆管炎患者长期肝移植结局比较：对器官共享联合网络（UNOS）数据库的过去十年分析
Dig Dis. 2025;43(5):569-581. doi: 10.1159/000547227. Epub 2025 Jul 4.
6
Dietary lipophilic index and odds of metabolic dysfunction-associated steatotic liver disease (MASLD): A population-based study.饮食亲脂性指数与代谢功能障碍相关脂肪性肝病（MASLD）的患病几率：一项基于人群的研究。
Dig Liver Dis. 2025 Jul;57(7):1455-1464. doi: 10.1016/j.dld.2025.04.001. Epub 2025 May 13.
7
Associations between high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and their ratio with metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study.高密度脂蛋白胆固醇、非高密度脂蛋白胆固醇及其比值与代谢功能障碍相关脂肪性肝病的关联：一项回顾性队列研究
Front Endocrinol (Lausanne). 2025 Jun 18;16:1585811. doi: 10.3389/fendo.2025.1585811. eCollection 2025.
8
Associations between MASLD phenotypes and the risk of carotid artery plaque: a cross-sectional study among railway workers.代谢功能障碍相关脂肪性肝病（MASLD）表型与颈动脉斑块风险之间的关联：一项铁路工人的横断面研究
Acta Diabetol. 2025 Jun 24. doi: 10.1007/s00592-025-02536-w.
9
Identification of Preclinical Biomarkers of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) versus MASLD and Increased Alcohol Intake and the Impact of Diet.代谢功能障碍相关脂肪性肝病（MASLD）与MASLD合并酒精摄入量增加的临床前生物标志物的鉴定以及饮食的影响。
Am J Pathol. 2025 Jun 12. doi: 10.1016/j.ajpath.2025.05.013.
10
Serum Tsukushi level is negatively associated with cholesterol efflux capacity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.血清筑丝蛋白水平与代谢功能障碍相关脂肪性肝病中的胆固醇流出能力呈负相关：一项横断面研究。
Sci Rep. 2025 Jul 1;15(1):21883. doi: 10.1038/s41598-025-06431-w.
本文引用的文献
1
Nonalcoholic Fatty Liver Disease vs Metabolic-associated Fatty Liver Disease vs Metabolic Dysfunction-associated Steatotic Liver Disease: What's in the Name?非酒精性脂肪性肝病与代谢相关脂肪性肝病与代谢功能障碍相关脂肪性肝病：名称里有什么含义？
Euroasian J Hepatogastroenterol. 2024 Jan-Jun;14(1):1-4. doi: 10.5005/jp-journals-10018-1424.
2
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.有过量饮酒史患者脂肪性肝病新命名法的验证：一项前瞻性队列研究数据分析
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):218-228. doi: 10.1016/S2468-1253(23)00443-0. Epub 2024 Jan 11.
3
Definition of Metabolic Dysfunction: Shifting Goalposts.代谢功能障碍的定义：不断变化的目标
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101301. doi: 10.1016/j.jceh.2023.11.001. Epub 2023 Nov 7.
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识：新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
5
Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate.代谢相关脂肪性肝病：新命名及引发热议的处理方法
World J Hepatol. 2023 Feb 27;15(2):123-128. doi: 10.4254/wjh.v15.i2.123.
6
NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change.非酒精性脂肪性肝病（NAFLD）与代谢功能障碍相关脂肪性肝病（MAFLD）：南亚非酒精性脂肪性肝病患者不支持更改名称。
Euroasian J Hepatogastroenterol. 2022 Jul;12(Suppl 1):S1-S4. doi: 10.5005/jp-journals-10018-1363.
7
MAFLD: How is it different from NAFLD?MAFLD：与非酒精性脂肪性肝病（NAFLD）有何不同？
Clin Mol Hepatol. 2023 Feb;29(Suppl):S17-S31. doi: 10.3350/cmh.2022.0367. Epub 2022 Nov 29.
8
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?非酒精性脂肪性肝病（NAFLD）与代谢相关脂肪性肝病（MAFLD）。循证之辩已来，是否到了改变的时候？
Ann Hepatol. 2022 Nov-Dec;27(6):100765. doi: 10.1016/j.aohep.2022.100765. Epub 2022 Sep 28.
9
Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis.印度非酒精性脂肪性肝病的患病率：一项系统评价与荟萃分析。
J Clin Exp Hepatol. 2022 May-Jun;12(3):818-829. doi: 10.1016/j.jceh.2021.11.010. Epub 2021 Nov 25.
10
Lean Fatty Liver Disease: Through Thick and Thin.非酒精性脂肪性肝病：历经坎坷
J Clin Exp Hepatol. 2021 Sep-Oct;11(5):523-527. doi: 10.1016/j.jceh.2021.06.011. Epub 2021 Jun 18.
Zotero 插件